
Q/C TECHNOLOGIES, INC.
79
Recent developments include the appointment of a new Chief Technology Officer and ongoing strategic shifts focusing on the OPU Initiative. The company also faces Nasdaq compliance challenges and has announced changes in board composition and shareholder votes.
- Q/C Technologies appointed Yossef Ehrlichman as Chief Technology Officer in September 2026 to support its technology development efforts [N1].
- The company announced new board and shareholder votes in April 2026, reflecting governance activities [N2].
- TNF Pharmaceuticals and Renova Health announced a trial to explore isomyosamine in December 2024, which is related to the broader industry context but not directly to Q/C Technologies [N3].
Q/C Technologies, Inc. is a Nasdaq-listed company engaged in developing advanced optical computing technologies, specifically a silicon photonic computing architecture aimed at artificial intelligence inference. The company recently shifted its strategic focus away from a prior license agreement with LightSolver, which was terminated in June 2026. The new OPU Initiative is at an early development stage and involves significant technical challenges. The company has a seasoned board and executive team with expertise in medical, financial, and technological fields. Financially, the company reported a net loss in Q3 2026 but holds substantial cash and marketable securities, resulting in strong liquidity ratios. The company is currently addressing Nasdaq listing compliance issues related to its stock price.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Q/C Technologies, Inc. is focused on developing a proprietary silicon photonic computing architecture for AI inference following termination of a prior license agreement. The company reported a net loss of $941,793 for Q3 2026 and maintains strong liquidity with a current ratio of 5.06 as of September 30, 2026. The company faces Nasdaq listing compliance challenges due to its stock price being below the minimum bid requirement. Recent leadership appointments include a new Chief Technology Officer to advance its technology initiatives.
The company’s strategic pivot to the OPU Initiative represents a focused effort on a potentially transformative technology in silicon photonic computing for AI inference. The appointment of a Chief Technology Officer with relevant expertise supports the advancement of this initiative. Strong liquidity provides the company with resources to invest in research and development. The experienced board and management team bring diverse skills that may aid in navigating technical and market challenges.
The OPU Initiative is at an early stage with significant technical hurdles including analog precision, nonlinear computation, and memory integration. The company has reported net losses and faces Nasdaq listing compliance risks due to its stock price being below the minimum bid requirement. The termination of the prior license agreement and impairment charge indicate challenges in previous business lines. The company’s ability to develop commercially viable products and maintain listing status remains uncertain, posing risks to financial stability and investor confidence.
Q/C Technologies' moat is centered on its proprietary silicon photonic computing technology for AI inference, which is a specialized and technically challenging field. The company’s focus on optical computing and its intellectual property position could provide differentiation if successfully developed. However, the technology is at an early stage, and the company faces competition from firms with greater resources. The expertise of its leadership and recent CTO appointment contribute to its capability to advance its technology.
• Nasdaq Listing Compliance Risk: The company’s common stock price was below Nasdaq’s minimum bid price requirement as of September 30, 2026, and it received a deficiency notice with a compliance period until May 5, 2027. Failure to regain compliance could lead to delisting, adversely affecting liquidity and stock price.
• Early Stage Technology Development: The OPU Initiative is at an early development stage with significant technical challenges that require substantial time, capital, and specialized personnel. Failure to develop viable products could materially affect the company’s business and financial condition.
• Financial Performance and Goodwill Impairment: The company reported a net loss for Q3 2026 and holds a significant portion of goodwill on its balance sheet. Market capitalization is below stockholders’ equity, which could lead to goodwill impairment and affect financial statements and Nasdaq equity requirements.
Business trends: Strategic pivot to proprietary silicon photonic computing for AI inference; ongoing governance and leadership updates.
Execution milestones: Development of OPU Initiative prototypes; compliance with Nasdaq listing requirements; integration of new CTO leadership.
Key risks: Technical challenges in early-stage technology; Nasdaq listing compliance risk due to stock price; financial pressures including net losses and goodwill impairment.
High visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Q/C Technologies, Inc. is a publicly traded company on The Nasdaq Stock Market under the ticker QCLS [S1].
- As of September 30, 2026, the company had cash and cash equivalents of $2,585,051 and short-term investments of $6,805,270, totaling current assets of $10,199,419 against current liabilities of $2,017,369, resulting in a current ratio of 5.06 and a cash ratio of 4.65 [S2].
- The company reported a net loss of $941,793 for the quarter ended September 30, 2026, with basic and diluted earnings per share of -$0.14 [S2].
- Goodwill represented approximately 49% of total assets as of September 30, 2026, amounting to $10,498,539 [S2].
- The company terminated its license agreement with LightSolver on June 26, 2026, recording an impairment charge of $3,177,999 and shifted strategic focus to its OPU Initiative, which is an early-stage proprietary silicon photonic computing architecture for artificial intelligence inference [S2].
- The OPU Initiative involves significant technical challenges and requires substantial time, capital, and specialized engineering personnel, including a recently appointed Chief Technology Officer [S2].
- The company’s common stock price was $0.85 per share on September 30, 2026, below Nasdaq’s minimum bid price requirement of $1.00, and the company received a deficiency notice with a compliance period until May 5, 2027 [S2].
- The company’s board of directors and executive officers include experienced professionals such as Dr. Mitchell Glass (Chief Medical Officer), Ian Rhodes (Interim CFO), Joshua Silverman (Executive Chairman), and others with backgrounds in finance, medicine, and technology [S1].
- On September 15, 2026, Q/C Technologies appointed Yossef Ehrlichman as Chief Technology Officer to support its technology development efforts [N1].
- The company has adopted a Code of Business Ethics and Conduct applicable to its board, officers, and employees, with oversight by a Risk and Disclosure Committee [S1].
Generated 2026-11-16
- S1 | 2026-04-29 | 10-K/A
- S2 | 2026-11-16 | 10-Q
- N1 | 2026-09-15 | www.nasdaq.com | Q/C Technologies Appoints Yossef Ehrlichman As Chief Technology Officer | https://www.nasdaq.com/articles/q-c-technologies-appoints-yossef-ehrlichman-chief-technology-officer
- N2 | 2026-04-16 | www.nasdaq.com | TNF Pharmaceuticals Announces New Board and Shareholder Votes | https://www.nasdaq.com/articles/tnf-pharmaceuticals-announces-new-board-and-shareholder-votes
- N3 | 2024-12-19 | www.nasdaq.com | TNF Pharmaceuticals, Renova Health announce trial to explore isomyosamine | https://www.nasdaq.com/articles/tnf-pharmaceuticals-renova-health-announce-trial-explore-isomyosamine
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


